Can we cure refractory Hodgkin’s lymphoma with transplantation?

Ciurea, Stefan O.; Kongtim, Piyanuch; Srour, Samer A.; Saini, Neeraj; Im, Jin S.; Ramdial, Jeremy; Khouri, Issa F.; Anderlini, Paolo; Popat, Uday; Hosing, Chitra; Champlin, Richard E.; Lee, Hun J.; Fayad, Luis; Hagemeister, Fredrick B.; Bica, Ana; Lipan, Lavinia; Crăciun, O; Jercan, Cristina; Tănase, Alina; Coliţă, Anca

doi:10.1038/s41409-020-0989-z

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All relapses happened within the first year of transplant. This study, albeit small, shows very encouraging data in a difficult-to-treat group of patients [52].…”

Section: Role Of Alternative Donor Hsct In Relapsed or Refractory Chlmentioning

confidence: 66%

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes

Al-Juhaishi

Borogovac

Ibrahimi

et al. 2022

JPM

View full text Add to dashboard Cite

Hodgkin’s lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure for many with chemotherapy-responsive lymphoma. Patients who relapse after autologous transplant or those with chemorefractory disease have poor prognosis and represent a high unmet need. Allogeneic hematopoietic stem cell transplantation provides a proven curative therapy for these patients and should be considered, especially in young and medically fit patients. The use of newer agents in this disease such as brentuximab vedotin and immune checkpoint inhibitors can help bring more patients to transplantation and should be considered as well.

show abstract

“…All relapses happened within the first year of transplant. This study, albeit small, shows very encouraging data in a difficult-to-treat group of patients [52].…”

Section: Role Of Alternative Donor Hsct In Relapsed or Refractory Chlmentioning

confidence: 66%

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes

Al-Juhaishi

Borogovac

Ibrahimi

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

Haploidentical Stem Cell Transplantation in Lymphomas—Expectations and Pitfalls

Mariotti

Bramanti

Santoro

et al. 2020

JCM

View full text Add to dashboard Cite

T-cell replete Haploidentical stem cell transplantation (Haplo-SCT) with Post-transplant cyclophosphamide (PT-Cy) is an emerging therapeutic option for patients with advanced relapsed or refractory lymphoma. The feasibility of this platform is supported by several retrospective studies showing a toxicity profile that is improved relative to umbilical cord blood and mismatched unrelated donor (UD) transplant and comparable to matched unrelated donor transplant. In particular, cumulative incidence of chronic graft-versus-host disease (GVHD) is reduced after Haplo-SCT relative to UD and matched related donor (MRD) transplant thanks to PT-Cy employed as GVHD prophylaxis. This achievement, together with a similar incidence of acute GVHD and disease relapse, results in a promising advantage of Haplo-SCT in terms of relapse-free/GVHD free survival. Unmet needs of the Haplo-SCT platform are represented by the persistence of a not negligible rate of non-relapse mortality, especially due to infections and disease relapse. Future efforts are warranted in order to reduce life-threatening infections and to employ Halo-SCT with PT-Cy as a platform to build new immunotherapeutic strategies.

show abstract

Can we cure refractory Hodgkin’s lymphoma with transplantation?

Cited by 2 publications

References 12 publications

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes

Haploidentical Stem Cell Transplantation in Lymphomas—Expectations and Pitfalls

Contact Info

Product

Resources

About